Instadose Pharma (Instadose Pharma) Cash-to-Debt : 0.02 (As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Instadose Pharma's cash to debt ratio for the quarter that ended in Feb. 2022 was 0.02.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Instadose Pharma couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2022.

The historical rank and industry rank for Instadose Pharma's Cash-to-Debt or its related term are showing as below:

INSD's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.92
* Ranked among companies with meaningful Cash-to-Debt only.

Instadose Pharma Cash-to-Debt Historical Data

The historical data trend for Instadose Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Instadose Pharma Cash-to-Debt Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

N/A

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Cash-to-Debt	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	0.02

Competitive Comparison of Instadose Pharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instadose Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's Cash-to-Debt falls into.

Instadose Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Instadose Pharma's Cash to Debt Ratio for the fiscal year that ended in Nov. 2021 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Instadose Pharma's Cash to Debt Ratio for the quarter that ended in Feb. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.004	/	(0.123	+	0.065)
	=	0.02

Instadose Pharma (OTCPK:INSD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Instadose Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.